Physician profile
Stephen Sargent
NPI 1801878145
$5,489.09
in general payments reported to CMS, 2019-2025
50 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,085 · 2020: $399 · 2021: $60.31 · 2022: $62.53 · 2023: $737 · 2024: $1,024 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821 · Education: $61.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,821.46 |
| Education | $61.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $824.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Novo Nordisk INC | $767.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $412.37 | 2019-2025 | |
| Abbvie INC. | $387.13 | 2020-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $364.25 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $348.05 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $325.10 | 2019-2025 | Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $243.14 | 2019-2024 | Takhzyro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.16 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $191.95 | 2019-2025 | Gardasil 9, M-M-R II, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $159.61 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $85.55 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $82.80 | 2019-2025 | Austedo Xr |
| Astellas Pharma US INC | $68.54 | 2019-2024 | Veozah |
| Biocryst US Sales Co., LLC | $58.94 | 2023 | Orladeyo |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Sargent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.